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lower tendency of bleeding and in reducing stroke incidences. This study aims to 
compare the pattern of anticoagulants used and to assess their safety and efficacy 
by evaluating bleeding and stroke occurrences in both groups. Methods: This is a 
retrospective study carried out at a hospital with hematology clinic in the state of 
Selangor, Malaysia. The samples of the study were patients with atrial fibrillation, 
prescribed with warfarin or dabigatran. Data collected includes patients’ demo-
graphics, co-morbidities, and stroke and haemorrhage events. Results: A total of 
71 patients were recruited in this study with 21, 21 and 29 patients were on Warfarin, 
Dabigatran 110 mg and Dabigatran 150 mg respectively. Out of 50 Dabigatran users, 
36 of them are warfarin-experienced. 1 out of 21 patients on warfarin experienced 
stroke while none in both 110 and 150mg dabigatran group. A total of 11 (52.4%) 
of warfarin patients experienced bleeding with 2 of them having major bleeding 
whereas, only 4 (8%) out of 50 dabigatran patients experienced minor bleeding, 
1 in patient who were on Dabigatran 150mg and 3 patients who were on Dabigatran 
110mg. ConClusions: The pattern of anticoagulant used for stroke prophylaxis 
in atrial fibrillation is slowly changing from Warfarin to Dabigatran. Evaluation of 
safety and efficacy profile of Warfarin shows that Warfarin requires more extensive 
management and monitoring in order to achieve therapeutic goals with fewer side 
effects. Comparison between both anticoagulants show that Dabigatran is safer and 
more effective compared to warfarin.
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objeCtives: In patients receiving long-term low-dose aspirin for prevention of 
adverse cardiovascular (CV) events, proton pump inhibitors (PPIs) are often prescribed 
to prevent aspirin-induced gastrointestinal bleeding. However, PPIs may reduce the 
therapeutic efficacy of aspirin. This study investigated the effect of co-administration 
of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the 
risk of recurrence of such a CV event. Methods: A retrospective cohort study using 
the Clinical Practice Research Datalink (CPRD) was conducted in patients with at least 
one occurrence of AMI or stroke between 1998 and 2014, and who received at least 
one prescription of aspirin (30-325 mg/day) after the first AMI or stroke. Concomitant 
use of aspirin and PPIs was defined as overlaps between periods of current use of 
aspirin and of PPIs. The hazard ratio (HR; i.e. the instantaneous risk in concomitant 
use of aspirin and PPIs relative to that in aspirin use alone) was estimated using 
a Cox proportional hazards model with time-varying covariates. The estimate was 
adjusted for multiple potential confounders such as age, BMI, socioeconomic status, 
smoking status and history of diabetes. Results: The study population consisted of 
39,794 patients. During the follow-up period [range: 0.0-16.9 years; mean (SD): 4.1 (3.8) 
years], 18,094 patients had no prescription of PPIs, and 13,013 patients concomitantly 
used aspirin and PPIs for a cumulative duration longer than 50% of the cumulative 
duration of aspirin use. AMI or stroke recurred in 4,307 patients, with mean (SD) time 
from the first to the second event being 2.6 (2.7) years. Adjusted HR (95% CI) of AMI 
or stroke in aspirin plus PPIs versus aspirin use was 1.23 (1.07-1.41). ConClusions: 
Co-administration of PPIs in aspirin users with a first AMI or stroke is associated with 
an increased risk of recurrence of such a CV event.
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objeCtives: The management of SI in patients at high CV risk is poorly understood 
within Canada. The present study was conducted to describe SI patient characteris-
tics and their management and to estimate the incidence in the high-risk popula-
tion. Methods: We retrospectively analysed data from an open cohort of patients 
initiating statin therapy between 2004 and 2012, using the Southwestern Ontario 
primary-care practice database. Inclusion criteria were: diagnosis of dyslipidaemia, ≥ 1 
statin prescription, and ≥ 2 years of statin-free baseline data. SI index date was identi-
fied as the first occurrence of SI-related symptoms associated with a change in statin 
therapy. Patients were stratified into three CV risk levels (low, intermediate, high). 
Here, we report results for the high-risk subgroup. Results: Of 41,733 patients who 
initiated statin therapy, 14,607 were at high CV risk; 1,294 patients in this subgroup 
had SI. The mean±SD age was 61±8.9 years, 53% (n= 684) were male, and low-density 
lipoprotein cholesterol (LDL-C) was 2.8±1.1 mmol/L. Among patients identified with 
SI, 13% (n= 170) experienced myopathy and 87% (n= 1124) had SI-related symptoms. 
There were nine rhabdomyolysis cases, two resulting in hospitalization. Statins were 
discontinued in 412 (32%) patients, and 677 (52%) patients had their statin dosage 
decreased. At the SI index date 84% (n= 1085) of patients were on LDL-C target, with 
the on-target proportion decreasing to 49% (n= 638) 6 months post-SI. Among the 656 
patients off-target at 6 months post-SI, 28% (n= 185) decreased statin dose or stopped 
statins, and 46% (n= 299) were switched to a non-statin therapy. ConClusions: SI 
affects the optimal treatment of dyslipidaemia in this high-risk population. A number 
of patients do not achieve their LDL-C target and are undertreated because they do 
not tolerate their initial statin dose or have to be treated with a non-statin therapy. 
These patients are at increased CV risk.
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with and without a new CVE between 01/01/2006 and 06/30/2012. CVEs included pri-
mary inpatient claims for myocardial infarction (MI), unstable angina (UA), ischemic 
stroke (IS), transient ischemic attack, revascularization and heart failure. Patients 
were stratified into two CV risk cohorts: history of cardiovascular disease (CVD) [MI, 
UA, coronary artery bypass graft, percutaneous coronary intervention, IS] and coro-
nary heart disease risk equivalent (CHD RE) [peripheral artery disease, abdominal 
aortic aneurysm, coronary artery disease, diabetes, dyslipidemia]. Propensity score 
matching was applied to compare the burden among patients with and without a 
new CVE, ranging from 1 month through 3 years post-CVE date. ConClusions: 
High-risk hyperlipidemia patients with new CVEs had significantly higher burden of 
hospitalizations and healthcare visits compared to matched patients without new 
CVEs, evident in the 1st month and sustained through 3 years post-CVE.
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objeCtives: To compare the effectiveness and safety of oral anticoagulants (OACs) 
-NOAC and VKA- in patients with atrial fibrillation (AF) in real-world clinical prac-
tice. Methods: Retrospective population-based cohort study. All new users of OAC 
from Nov2011 to Feb2014 with AF were included (N= 21841). Data were obtained by 
linking diverse electronic databases of the Valencia Region, Spain. Incidence rates 
were estimated. Cox proportional hazards models adjusted for sociodemographic, 
clinical, healthcare use data, and propensity scores assessed the risk of several 
outcomes on effectiveness and safety of each NOAC compared with acenocumarol. 
Apixaban and warfarin patients were excluded because of few person-time obser-
vations Results: The incidence of ischemic stroke was 12.5, 8.7 and 10.8 per 1000 
person-years for acenocumarol, dabigatran and rivaroxaban. After adjustment 
no differences were found for NOAC in the risk of ischemic stroke compared to 
acenocumarol (HR:0.78, 95%CI:0.51-1.20 for dabigatran; HR:0.76, 95%CI:0.42-1.35 
for rivaroxaban). Regarding the incidence of mortality (80.2, 65.1 and 91.7, respec-
tively) no increased risk was found (HR:0.96, 95%CI:0.81-1.12 for dabigatran; HR: 1.16, 
95%CI:0.95-1.42 for rivaroxaban). The incidence of gastrointestinal bleeding was 18.3, 
21.4 and 14.4, respectively, being dabigatran associated with a higher risk (HR:1.44, 
95%CI:1.08-1.92) but not rivaroxaban (HR: 0.72, 95%CI: 0.43-1.19). However, no dif-
ferences were found for major gastrointestinal bleeding (HR: 1.01, 95%CI: 0.59-1.73 
for dabigatran; HR:0.43, 95%CI:0.16-1.17 for rivaroxaban). Regarding the incidence 
of intracranial haemorrhage (8.8, 3.0 and 5.4, respectively), dabigatran was found to 
be associated with a decreased risk (HR:0.36, 95%CI:0.18-0.74), and no differences 
for rivaroxaban (HR: 0.56, 95%CI 0.25-1.27). ConClusions: NOAC were not associ-
ated with an increased risk of stroke or death compared with acenocumarol among 
newly treated patients with AF. Dabigatran was associated with lower risk of intrac-
ranial haemorrhage and higher risk of gastrointestinal bleeding. The risk of major 
gastrointestinal bleeding related to NOAC was similar to that for acenocumarol.
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objeCtives: Warfarin is an oral anticoagulant prescribed as prophylaxis for patients 
with high risk of developing thrombosis, pulmonary embolism as well as treatment 
for recurrent and idiopathic incident of pulmonary embolism. This study aims to 
compare time in therapeutic range (TTR) of warfarin in patients with pulmonary 
embolism with bleeding and stroke and determine reasons of INR falling out of 
range. Methods: This is a retrospective study carried out at a tertiary-care hospital 
with anticoagulation clinic in the state of Selangor, Malaysia. The samples of the 
study were patients with pulmonary embolism, prescribed with warfarin from year 
2009 to 2014. The data collected includes patients’ demographics, co-morbidities, 
and international normalized ratio (INR). TTR was determined using Rosendaal 
method. Patients’ stroke, haemorrhage events and reasons of INR being outside the 
range were recorded. Results: TTR of 20 out of 30 patients (66.67%) were found to 
be outside the range (< 75%) with 8 of them (40%) experiencing bleeding. The remain-
ing 10 patients (33.33%) recorded TTR of more than 75%, where 3 of them (30%) 
experienced bleeding during their warfarin treatment. Out of the total 11 patients 
who bled, 10 of them had minor bleeding. The other 1 patient from TTR < 75% group 
had major bleeding. None of the patients from both groups experienced stroke. The 
highest identified reason of International Normalized Range (INR) being outside 
the range was found to be drug-drug interactions, which were seen in 9 patients 
(30%). ConClusions: Warfarin treatment should be maintained within the tar-
geted INR range to avoid unwanted events such as bleeding and stroke. Based on the 
findings of this study, it can be concluded that warfarin monitoring should be done 
continuously and thoroughly to ensure that INR level falls within the targeted range.
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objeCtives: Warfarin has been used for more than 50 years as stroke prophylaxis 
in patients with atrial fibrillation. New oral anticoagulant, Dabigatran, was devel-
oped and shown to be safer and more efficacious compared to Warfarin due to its 
